omeprazole- omeprazole capsule, delayed release
cardinal health - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within 4 weeks. some patients may require an additional 4 weeks of therapy. omeprazole delayed-release capsules, in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to one year history) to eradicate h. pylori in adults. omeprazole delayed-release capsules, in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.1) and dosage and administration (2)]. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in pati
hiprabovis ibr marker live
laboratorios hipra s.a - live ge- tk- double-gene-deleted bovine herpes virus type 1, strain ceddel: 106.3–107.3 ccid50 - immunologicals - cattle - for the active immunisation of cattle from three months of age against bovine herpes virus type 1 (bohv-1) to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion.onset of immunity: 21 days after completion of the basic vaccination scheme.duration of immunity: 6 months after completion of the basic vaccination scheme
rhiniseng
laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer / recombinant type-d pasteurella-multocida toxin (pmtr) - immunologicals - pigs (gilts and sows) - for the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with bordetella-bronchiseptica and pasteurella-multocida infections during the fattening period. challenge studies have demonstrated that passive immunity lasts until piglets are six weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.
startvac
laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - immunologicals for bovidae - cattle (cows and heifers) - for herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by staphylococcus aureus, coliforms and coagulase-negative staphylococci.the full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection (equivalent to 130 days post-parturition).
selectan solution for injection for cattle and pigs
laboratorios hipra s.a. - florfenicol - parenteral liquid/solution/suspension - florfenicol antibiotic active 300.0 mg/ml - antibiotic & related
etonogestrel/ ethinylestradiol laboratorios leon farma 0.12 mg/24 h - 0.015 mg/24 h vagin. delivery system sachet
laboratorios león farma s.a. - ethinylestradiol 3,474 mg; etonogestrel 11 mg - vaginal delivery system - 0,120 mg/24 h - 0,015 mg/24 h - etonogestrel 11 mg; ethinylestradiol 3.474 mg - vaginal ring with progestogen and estrogen
tapentadol retard laboratorios liconsa 100 mg tabl. prol.-rel.
laboratorios liconsa s.a. - tapentadol tartrate 167,81 mg - eq. tapentadol 100 mg - prolonged-release tablet - tapentadol
tapentadol retard laboratorios liconsa 150 mg tabl. prol.-rel.
laboratorios liconsa s.a. - tapentadol tartrate 251,715 mg - eq. tapentadol 150 mg - prolonged-release tablet - tapentadol
tapentadol retard laboratorios liconsa 200 mg tabl. prol.-rel.
laboratorios liconsa s.a. - tapentadol tartrate 335,62 mg - eq. tapentadol 200 mg - prolonged-release tablet - tapentadol
tapentadol retard laboratorios liconsa 25 mg tabl. prol.-rel.
laboratorios liconsa s.a. - tapentadol tartrate 41,9525 mg - eq. tapentadol 25 mg - prolonged-release tablet - tapentadol